Clinical trial
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
NCT06264180 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
- Lead sponsor
- Replimune, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 11, 2024
- Completion date
- March 31, 2031
- Enrollment
- 400 (estimated)
- Sites
- 81
Conditions
As the registry lists them; a condition with its own page is linked.
advanced melanoma